Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Proteostasis Therapeutics Inc    PTI

PROTEOSTASIS THERAPEUTICS INC (PTI)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

PROTEOSTASIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2018 | 01:58pm CEST

Item 1.01 Entry into a Material Definitive Agreement.

In contemplation of its previously-announced move to a new headquarters location in Boston, MA, Proteostasis Therapeutics, Inc. (the "Company") and its current landlord amended the lease for the Company's existing office space (located at 200 Technology Square, Cambridge, Massachusetts) to accelerate the expiration date of the lease to May 3, 2018 (the term was originally scheduled to expire on May 31, 2018). The amendment, effective as of April 13, 2018, also defined the terms of surrender of the existing space.

The foregoing description of the amendment to the lease does not purport to be complete and is qualified in its entirety by reference to such agreement, which the Company intends to file as an exhibit to its next periodic report filed under the Securities Exchange Act of 1934, as amended, that corresponds to the period in which the lease amendment was executed.

Item 8.01 Other Events.

On April 17, 2018, Proteostasis Therapeutics, Inc. announced that the study protocol to investigate PTI-428 in CF patients on background SymdekoTM therapy has received endorsement from the Therapeutics Development Network (TDN), the drug development arm of the Cystic Fibrosis Foundation (CFF). The Phase 2 study is designed to investigate the safety, tolerability and pharmacokinetics (PK) of multiple doses of PTI-428 in a 28-day dosing study. The Company plans to start dosing Cystic Fibrosis patients in the third quarter of this year and aims to share initial results in early 2019.

Safe Harbor

To the extent that statements in this Form 8-K are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this Form 8-K include, without limitation, statements regarding expected timing of the initiation of, patient enrollment in, data from, and the completion of, our clinical studies and cohorts for PTI-428 and the expected benefits of TDN endorsement. Forward-looking statements made in this Form 8-K involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility FDA protocol comments delay or do not permit trial commencement, or the FDA requires us to run cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2017 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Symdeko™ is a trademark of Vertex Pharmaceuticals Incorporated.

The above information is not an admission as to the materiality of any information therein. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROTEOSTASIS THERAPEUTICS
08/08PROTEOSTASIS THERAPEUTICS : Management's Discussion and Analysis of Financial Co..
AQ
07/26PROTEOSTASIS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements..
AQ
07/20Free Pre-Market Technical Recap on Axovant Sciences and Three Additional Biot..
AC
06/25PROTEOSTASIS THERAPEUTICS : Added to the Russell 3000® Index
PR
06/19PROTEOSTASIS THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Ho..
AQ
06/08PROTEOSTASIS THERAPEUTICS INC : Today’s Research Reports on Stocks to Watch: Pro..
AC
06/08PROTEOSTASIS THERAPEUTICS : Announces Positive Data from Ongoing Phase 1 Study o..
AQ
06/06PROTEOSTASIS THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financ..
AQ
06/06PROTEOSTASIS THERAPEUTICS : Announces Positive Data from Ongoing Phase 1 Study o..
PR
06/01PROTEOSTASIS THERAPEUTICS : Announces Presentations at the 41st European Cystic ..
PR
More news
News from SeekingAlpha
06/27Translate Bio prices upsized initial public offering 
06/19Translate Bio Prepares For $100 Million U.S. IPO 
06/12Kerrisdale Capital Drills Down On A Few Shorts (Podcast) 
06/11YOUR DAILY PHARMA SCOOP : Scynexis Moves Up, Proteostasis Disappoints Investors,.. 
06/08Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; inv.. 
Financials ($)
Sales 2018 4,04 M
EBIT 2018 -60,7 M
Net income 2018 -59,7 M
Finance 2018 25,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 16,2x
EV / Sales 2019 14,6x
Capitalization 90,3 M
Chart PROTEOSTASIS THERAPEUTICS INC
Duration : Period :
Proteostasis Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTEOSTASIS THERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 13,5 $
Spread / Average Target 449%
EPS Revisions
Managers
NameTitle
Meenu Chhabra Karson President, Chief Executive Officer & Director
Michael James Barrett Chairman
Marija Zecevic Chief Operating Officer
Helen M. Boudreau Treasurer, Chief Financial & Accounting Officer
Po-Shun Lee Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOSTASIS THERAPEUTICS INC-55.75%90
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.46%46 021
REGENERON PHARMACEUTICALS3.00%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170